These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

449 related articles for article (PubMed ID: 22668349)

  • 1. Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells.
    Yuen HF; Abramczyk O; Montgomery G; Chan KK; Huang YH; Sasazuki T; Shirasawa S; Gopesh S; Chan KW; Fennell D; Janne P; El-Tanani M; Murray JT
    Biosci Rep; 2012 Aug; 32(4):413-22. PubMed ID: 22668349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways.
    Yuen HF; Chan KK; Grills C; Murray JT; Platt-Higgins A; Eldin OS; O'Byrne K; Janne P; Fennell DA; Johnston PG; Rudland PS; El-Tanani M
    Clin Cancer Res; 2012 Jan; 18(2):380-91. PubMed ID: 22090358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.
    Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Koch A; Evers BM
    Anticancer Res; 2010 Dec; 30(12):4951-8. PubMed ID: 21187475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
    Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Evers BM
    J Surg Res; 2012 Aug; 176(2):542-8. PubMed ID: 22261591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphoinositide 3-kinase/AKT/mTORC1/2 signaling determines sensitivity of Burkitt's lymphoma cells to BH3 mimetics.
    Spender LC; Inman GJ
    Mol Cancer Res; 2012 Mar; 10(3):347-59. PubMed ID: 22241218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PI3K/Akt-sensitive MEK-independent compensatory circuit of ERK activation in ER-positive PI3K-mutant T47D breast cancer cells.
    Aksamitiene E; Kholodenko BN; Kolch W; Hoek JB; Kiyatkin A
    Cell Signal; 2010 Sep; 22(9):1369-78. PubMed ID: 20471474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA.
    Gulhati P; Zaytseva YY; Valentino JD; Stevens PD; Kim JT; Sasazuki T; Shirasawa S; Lee EY; Weiss HL; Dong J; Gao T; Evers BM
    Carcinogenesis; 2012 Sep; 33(9):1782-90. PubMed ID: 22696593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin-like growth factor I-mediated protection from rapamycin-induced apoptosis is independent of Ras-Erk1-Erk2 and phosphatidylinositol 3'-kinase-Akt signaling pathways.
    Thimmaiah KN; Easton J; Huang S; Veverka KA; Germain GS; Harwood FC; Houghton PJ
    Cancer Res; 2003 Jan; 63(2):364-74. PubMed ID: 12543789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
    Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
    Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. mTORC1 inhibition and ECM-cell adhesion-independent drug resistance via PI3K-AKT and PI3K-RAS-MAPK feedback loops.
    Galoian K; Temple HT; Galoyan A
    Tumour Biol; 2012 Jun; 33(3):885-90. PubMed ID: 22246604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Downstream effectors of oncogenic ras in multiple myeloma cells.
    Hu L; Shi Y; Hsu JH; Gera J; Van Ness B; Lichtenstein A
    Blood; 2003 Apr; 101(8):3126-35. PubMed ID: 12515720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling.
    Halilovic E; She QB; Ye Q; Pagliarini R; Sellers WR; Solit DB; Rosen N
    Cancer Res; 2010 Sep; 70(17):6804-14. PubMed ID: 20699365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo.
    Hofmann I; Weiss A; Elain G; Schwaederle M; Sterker D; Romanet V; Schmelzle T; Lai A; Brachmann SM; Bentires-Alj M; Roberts TM; Sellers WR; Hofmann F; Maira SM
    PLoS One; 2012; 7(8):e44146. PubMed ID: 22952903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma.
    Steinbrunn T; Stühmer T; Sayehli C; Chatterjee M; Einsele H; Bargou RC
    Br J Haematol; 2012 Nov; 159(4):430-40. PubMed ID: 22985491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early activation of mTORC1 signalling in response to mechanical overload is independent of phosphoinositide 3-kinase/Akt signalling.
    Miyazaki M; McCarthy JJ; Fedele MJ; Esser KA
    J Physiol; 2011 Apr; 589(Pt 7):1831-46. PubMed ID: 21300751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. K-Ras mutation-mediated IGF-1-induced feedback ERK activation contributes to the rapalog resistance in pancreatic ductal adenocarcinomas.
    Wei F; Liu Y; Bellail AC; Olson JJ; Sun SY; Lu G; Ding L; Yuan C; Wang G; Hao C
    Cancer Lett; 2012 Sep; 322(1):58-69. PubMed ID: 22342683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined blockade of signalling pathways shows marked anti-tumour potential in phaeochromocytoma cell lines.
    Nölting S; Garcia E; Alusi G; Giubellino A; Pacak K; Korbonits M; Grossman AB
    J Mol Endocrinol; 2012 Oct; 49(2):79-96. PubMed ID: 22715163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.
    Shoji K; Oda K; Kashiyama T; Ikeda Y; Nakagawa S; Sone K; Miyamoto Y; Hiraike H; Tanikawa M; Miyasaka A; Koso T; Matsumoto Y; Wada-Hiraike O; Kawana K; Kuramoto H; McCormick F; Aburatani H; Yano T; Kozuma S; Taketani Y
    PLoS One; 2012; 7(5):e37431. PubMed ID: 22662154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition.
    Shi H; Kong X; Ribas A; Lo RS
    Cancer Res; 2011 Aug; 71(15):5067-74. PubMed ID: 21803746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. mTORC1 inhibition increases neurotensin secretion and gene expression through activation of the MEK/ERK/c-Jun pathway in the human endocrine cell line BON.
    Li J; Liu J; Song J; Wang X; Weiss HL; Townsend CM; Gao T; Evers BM
    Am J Physiol Cell Physiol; 2011 Jul; 301(1):C213-26. PubMed ID: 21508335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.